Over the past five years, the U.S. has emerged as the most coveted and valuable cannabis market in the world, but brands and investors are now seizing on opportunities that are exclusively European.
The region's cannabis market is predominately medical and in its early innings. Still, business interest escalated this year after two consequential transactions: Dublin-based Jazz Pharmaceuticals' acquisition of G.W. Pharmaceuticals, the manufacturer behind the only FDA-approved CBD treatment for seizures, and Curaleaf's acquisition of EMMAC Life Sciences, the largest vertically-integrated independent cannabis operator in Europe, Both transactions have prompted industry executives to reconsider Europe as a serious expansion target.
In emerging cannabis markets, the conventional approach is first to pursue plant-touching opportunities. But Europe's unique consumer habits and cannabis regulations have created an especially favorable environment for American vaporizer companies to flourish. Here's what makes the vape market so appealing.
The region is ripe for expansion.
www.greenentrepreneur.com